Mitochondria-Targeted Metal Polyphenol Networks Inhibit Crystalline Nephropathy by Modulating SerpinE1 and Remodeling...

Area of Science:

• Nanomedicine
• Renal Pathology
• Mitochondrial Targeting

Background:

• Crystalline nephropathy involves a cycle of tubular injury and crystal deposition.
• Current therapies and nanomedicines face delivery and targeting challenges.
• Natural antioxidants have poor bioavailability for kidney treatment.

Purpose of the Study:

• To develop a mitochondria-targeted nanomedicine to treat crystalline nephropathy.
• To overcome the glomerular filtration barrier and target redox imbalance.
• To inhibit crystal nucleation, growth, and aggregation in the kidney.

Main Methods:

• Synthesis of a 7.3 nm mitochondria-targeted metal-polyphenol network (Fe-PCA@TPP).
• In vitro studies on renal tubular cells assessing oxidative stress and apoptosis.
• In vivo studies in animal models evaluating kidney accumulation, crystal deposition, and renal function.

Main Results:

• Fe-PCA@TPP efficiently crossed the glomerular barrier and accumulated in mitochondria.
• The nanomedicine scavenged free radicals, restored redox homeostasis, and inhibited calcium oxalate crystal formation.
• In vivo, Fe-PCA@TPP reduced kidney crystal deposition, improved renal function, and decreased injury markers.

Conclusions:

• Fe-PCA@TPP is a size-compatible, mitochondria-targeted nanoplatform for crystalline nephropathy.
• It integrates crystal inhibition and redox regulation, targeting SerpinE1 to block oxidative stress-apoptosis.
• This nanomedicine offers a promising therapeutic strategy for crystalline nephropathy.